International audienceIn the past years, the demand for small batches of clinical grade plasmid DNA has been growing. For that purpose, we designed and qualified a scaled-down Good Manufacturing Practices (GMP) production method, able to produce small batches (1-4mg) of plasmid. The developed method does not require any complex production equipment and utilizes only disposable production materials, which makes it easy to implement and simplifies line-clearance. We have successfully used this method to produce several small batches of two different plasmids. The produced plasmids, both formulated in an Electroporation Buffer, are mixed and filled into small, single-use, aliquots. Quality control confirmed the robustness of the developed meth...
The introduction of new therapeutics requires validation of Good Manufacturing Practice (GMP)-grade ...
The use of plasmid DNA (pDNA) for human vaccines is a novel approach against leishmaniasis, a neglec...
The forthcoming arrival on the market of numerous protein therapeutics that require high clinical do...
International audienceIn the past years, the demand for small batches of clinical grade plasmid DNA ...
Gene therapy and genetic vaccines promise to revolutionize the treatment of inherited and ac-quired ...
Voß C, Schmidt T, Schleef M, Friehs K, Flaschel E. Production of supercoiled multimeric plasmid DNA ...
Malaria is a global health problem; an effective vaccine is urgently needed. Due to the relative pov...
Advancements in technology can improve industrial manufacturing, especially in the biopharmaceutical...
Minicircle DNA is a promising tool in the field of gene therapy, whose products are increasingly gai...
Plasmid DNA (pDNA) vaccine is a promising vaccine technology, with better safety profile, more econo...
The need to develop a robust method to produce large quantities of plasmid DNA has become vital due ...
Research leading to the thesis ‘Production and pharmaceutical formulation of plasmid DNA vaccines‘ c...
Plasmid DMA offers the promise of a new generation of pharmaceuticals that will address the often ov...
Abstract Background Although the use of induced blood stage malaria infection has proven to be a val...
The introduction of new therapeutics requires validation of Good Manufacturing Practice (GMP)-grade ...
The introduction of new therapeutics requires validation of Good Manufacturing Practice (GMP)-grade ...
The use of plasmid DNA (pDNA) for human vaccines is a novel approach against leishmaniasis, a neglec...
The forthcoming arrival on the market of numerous protein therapeutics that require high clinical do...
International audienceIn the past years, the demand for small batches of clinical grade plasmid DNA ...
Gene therapy and genetic vaccines promise to revolutionize the treatment of inherited and ac-quired ...
Voß C, Schmidt T, Schleef M, Friehs K, Flaschel E. Production of supercoiled multimeric plasmid DNA ...
Malaria is a global health problem; an effective vaccine is urgently needed. Due to the relative pov...
Advancements in technology can improve industrial manufacturing, especially in the biopharmaceutical...
Minicircle DNA is a promising tool in the field of gene therapy, whose products are increasingly gai...
Plasmid DNA (pDNA) vaccine is a promising vaccine technology, with better safety profile, more econo...
The need to develop a robust method to produce large quantities of plasmid DNA has become vital due ...
Research leading to the thesis ‘Production and pharmaceutical formulation of plasmid DNA vaccines‘ c...
Plasmid DMA offers the promise of a new generation of pharmaceuticals that will address the often ov...
Abstract Background Although the use of induced blood stage malaria infection has proven to be a val...
The introduction of new therapeutics requires validation of Good Manufacturing Practice (GMP)-grade ...
The introduction of new therapeutics requires validation of Good Manufacturing Practice (GMP)-grade ...
The use of plasmid DNA (pDNA) for human vaccines is a novel approach against leishmaniasis, a neglec...
The forthcoming arrival on the market of numerous protein therapeutics that require high clinical do...